Glucocorticoid Mediated Inhibition of LKB1 Mutant Non-Small Cell Lung Cancers

Authors

Kenneth E Huffman
Long Shan Li
Ryan Carstens
Hyunsil Park
Luc Girard
Kimberley Avila
Shuguang Wei
Rahul Kollipara
Brenda Timmons
Jessica Sudderth
Nawal Bendris
Jiyeon Kim
Pamela Villalobos
Junya Fujimoto
Sandra Schmid
Ralph J Deberardinis
Ignacio Wistuba
John Heymach
Ralf Kittler
Esra A Akbay
Bruce Posner
Yuzhuo Wang
Stephen Lam
Steven A Kliewer
David J Mangelsdorf
John D Minna

Publication Date

1-1-2023

Journal

Frontiers in Oncology

DOI

10.3389/fonc.2023.1025443

PMID

37035141

PMCID

PMC10078807

PubMedCentral® Posted Date

3-23-2023

PubMedCentral® Full Text Version

Post-print

Abstract

The glucocorticoid receptor (GR) is an important anti-cancer target in lymphoid cancers but has been understudied in solid tumors like lung cancer, although glucocorticoids are often given with chemotherapy regimens to mitigate side effects. Here, we identify a dexamethasone-GR mediated anti-cancer response in a subset of aggressive non-small cell lung cancers (NSCLCs) that harbor Serine/Threonine Kinase 11 (STK11/LKB1) mutations. High tumor expression of carbamoyl phosphate synthase 1 (CPS1) was strongly linked to the presence of LKB1 mutations, was the best predictor of NSCLC dexamethasone (DEX) sensitivity (

Keywords

LKB1, glucocorticoid, nuclear receptor, targeted therapy, lung cancer

Published Open-Access

yes

Recommended Citation

Huffman, Kenneth E; Li, Long Shan; Carstens, Ryan; et al., "Glucocorticoid Mediated Inhibition of LKB1 Mutant Non-Small Cell Lung Cancers" (2023). Faculty, Staff and Student Publications. 3311.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/3311